M. Todorovic-Balint, B. Balint, I. Djunić, Nevena Besevic, Andrej Pešić, O. Stojković
{"title":"移植物功能差的原因及可能的解决方法","authors":"M. Todorovic-Balint, B. Balint, I. Djunić, Nevena Besevic, Andrej Pešić, O. Stojković","doi":"10.2298/mpns22s1045t","DOIUrl":null,"url":null,"abstract":"Introduction. Poor graft function is one of the most severe complications after allogeneic hematopoietic stem cell transplantation, which manifests as pancytopenia/cytopenia in the blood count, with the presence of complete or incomplete donor chimerism. There are three entities of graft weakness: 1. poor graft function: pancytopenia with complete donor chimerism, 2. graft failure: pancytopenia with incomplete, i.e., mixed donor chimerism and 3. graft rejection: progressive decline of donor chimerism. Definition. Poor graft function is diagnosed as pancytopenia (hemoglobin < 70 g/L, absolute neutrophil count < 0.5 x 109/L, platelets < 20 x 109/L) for 3 consecutive days from D+28, excluding the presence of severe graft versus host disease and relapse, with complete donor chimerism in poor graft function, and incomplete in graft failure. Risk factors and therapeutic principles. The most common risk factors for poor graft function are a small dose of CD34+ hematopoietic stem cells in the transplant, graft versus host disease, cytomegalovirus infection, the presence of donor-specific antibodies, high serum ferritin, i.e., iron overload, as well as splenomegaly. Pathogenetic mechanisms in the development of poor graft function are still not fully elucidated. The role of the microenvironment of the patient?s bone marrow is also important, as well as disorders of the immune system Therapeutic options for overcoming this complication include using selected ?stem cell boost?, mesenchymal stem cells, and newer medical agents (N-acetyl cysteine, atorvastatin, thrombopoietin receptor agonists). Conclusion. The type of poor function of the graft is defined in relation to the percentage of donor chimerism, and is necessary for planning further treatment strategy.","PeriodicalId":87940,"journal":{"name":"Calcutta medical review","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Poor graft function - causes and potential solutions\",\"authors\":\"M. Todorovic-Balint, B. Balint, I. Djunić, Nevena Besevic, Andrej Pešić, O. Stojković\",\"doi\":\"10.2298/mpns22s1045t\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction. Poor graft function is one of the most severe complications after allogeneic hematopoietic stem cell transplantation, which manifests as pancytopenia/cytopenia in the blood count, with the presence of complete or incomplete donor chimerism. There are three entities of graft weakness: 1. poor graft function: pancytopenia with complete donor chimerism, 2. graft failure: pancytopenia with incomplete, i.e., mixed donor chimerism and 3. graft rejection: progressive decline of donor chimerism. Definition. Poor graft function is diagnosed as pancytopenia (hemoglobin < 70 g/L, absolute neutrophil count < 0.5 x 109/L, platelets < 20 x 109/L) for 3 consecutive days from D+28, excluding the presence of severe graft versus host disease and relapse, with complete donor chimerism in poor graft function, and incomplete in graft failure. Risk factors and therapeutic principles. The most common risk factors for poor graft function are a small dose of CD34+ hematopoietic stem cells in the transplant, graft versus host disease, cytomegalovirus infection, the presence of donor-specific antibodies, high serum ferritin, i.e., iron overload, as well as splenomegaly. Pathogenetic mechanisms in the development of poor graft function are still not fully elucidated. The role of the microenvironment of the patient?s bone marrow is also important, as well as disorders of the immune system Therapeutic options for overcoming this complication include using selected ?stem cell boost?, mesenchymal stem cells, and newer medical agents (N-acetyl cysteine, atorvastatin, thrombopoietin receptor agonists). Conclusion. The type of poor function of the graft is defined in relation to the percentage of donor chimerism, and is necessary for planning further treatment strategy.\",\"PeriodicalId\":87940,\"journal\":{\"name\":\"Calcutta medical review\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Calcutta medical review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2298/mpns22s1045t\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Calcutta medical review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2298/mpns22s1045t","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
介绍。移植物功能差是同种异体造血干细胞移植后最严重的并发症之一,表现为血细胞计数全减少/细胞减少,存在完全或不完全的供体嵌合。存在三种类型的嫁接弱点:1。移植物功能差:全血细胞减少伴完全供体嵌合;移植物失败:全血细胞减少伴不完全,即混合供体嵌合和3。移植物排斥反应:供体嵌合性逐渐下降。定义。移植物功能差的诊断为从D+28开始连续3天全血细胞减少(血红蛋白< 70 g/L,绝对中性粒细胞计数< 0.5 x 109/L,血小板< 20 x 109/L),排除严重移植物抗宿主病和复发,移植物功能差的供体嵌合完全,移植物功能不全。危险因素和治疗原则。移植物功能差最常见的危险因素是移植中CD34+造血干细胞的剂量小、移植物抗宿主病、巨细胞病毒感染、供体特异性抗体的存在、血清铁蛋白高(即铁超载)以及脾肿大。移植物功能不良的发病机制尚未完全阐明。患者微环境的作用?骨髓也很重要,免疫系统紊乱也是如此。克服这种并发症的治疗方法包括使用选择性的干细胞增强疗法。、间充质干细胞和较新的药物(n -乙酰半胱氨酸、阿托伐他汀、血小板生成素受体激动剂)。结论。移植物功能不良的类型与供体嵌合的百分比有关,这对于规划进一步的治疗策略是必要的。
Poor graft function - causes and potential solutions
Introduction. Poor graft function is one of the most severe complications after allogeneic hematopoietic stem cell transplantation, which manifests as pancytopenia/cytopenia in the blood count, with the presence of complete or incomplete donor chimerism. There are three entities of graft weakness: 1. poor graft function: pancytopenia with complete donor chimerism, 2. graft failure: pancytopenia with incomplete, i.e., mixed donor chimerism and 3. graft rejection: progressive decline of donor chimerism. Definition. Poor graft function is diagnosed as pancytopenia (hemoglobin < 70 g/L, absolute neutrophil count < 0.5 x 109/L, platelets < 20 x 109/L) for 3 consecutive days from D+28, excluding the presence of severe graft versus host disease and relapse, with complete donor chimerism in poor graft function, and incomplete in graft failure. Risk factors and therapeutic principles. The most common risk factors for poor graft function are a small dose of CD34+ hematopoietic stem cells in the transplant, graft versus host disease, cytomegalovirus infection, the presence of donor-specific antibodies, high serum ferritin, i.e., iron overload, as well as splenomegaly. Pathogenetic mechanisms in the development of poor graft function are still not fully elucidated. The role of the microenvironment of the patient?s bone marrow is also important, as well as disorders of the immune system Therapeutic options for overcoming this complication include using selected ?stem cell boost?, mesenchymal stem cells, and newer medical agents (N-acetyl cysteine, atorvastatin, thrombopoietin receptor agonists). Conclusion. The type of poor function of the graft is defined in relation to the percentage of donor chimerism, and is necessary for planning further treatment strategy.